Method for treating non-melanoma skin cancer by inducing UDP-glucuronosyltransferase activity using pterostilbene
View Patent ↗A method is provided for treating an individual for a cellular proliferative disorder, including administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene wherein UDP-glucuronosyltransferase (UGT) activity is increased. In an embodiment, 12-HETE levels can be reduced by administration of pterostilbene.
1. A method of treating an individual for a non-melanoma skin cancer, comprising administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene provided in a composition wherein UDP-glucuronosyltransferase (UGT) activity is increased, and wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 10% by weight based on the total weight of the composition.
2. The method of claim 1 , wherein the individual is a human.
3. The method of claim 2 , wherein the pterostilbene compound is provided in a composition comprising a pharmaceutically or nutraceutically acceptable carrier.
4. The method of claim 3 , wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 0.5% by weight based on the total weight of the composition.
5. The method of claim 3 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 5 mg to about 1000 mg.
6. The method of claim 3 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 50 mg to about 250 mg.
7. The method of claim 5 , wherein the route of administration of the compound is selected from the group consisting of oral, topical, intradermal, transdermal, and subcutaneous.
8. The method of claim 1 , wherein the non-melanoma skin cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell carcinoma, and cutaneous lymphoma.
9. The method of claim 8 , wherein the non-melanoma skin cancer is squamous cell carcinoma.
10. The method of claim 9 , further wherein 12-HETE levels are reduced in the squamous cell carcinoma.
11. The method of claim 1 , further wherein 12-HETE levels are reduced in the non-melanoma skin cancer.
12. A method of inhibiting UV-induced loss of UDP-glucuronosyltransferase (UGT) activity in an individual afflicted with a non-melanoma skin cancer, comprising administering to the individual in need of such treatment a therapeutically effective amount of the compound pterostilbene provided in a composition wherein UDP-glucuronosyltransferase (UGT) activity is increased, and wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 10% by weight based on the total weight of the composition.
13. The method of claim 12 , wherein the individual is a human.
14. The method of claim 13 , wherein the pterostilbene compound is provided in a composition comprising a pharmaceutically or nutraceutically acceptable carrier.
15. The method of claim 14 , wherein the therapeutically effective amount of pterostilbene for a total dose is in a range of about 0.1% by weight to about 0.5% by weight based on the total weight of the composition.
16. The method of claim 14 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 5 mg to about 1000 mg.
17. The method of claim 14 , wherein the therapeutically effective amount of pterostilbene for a total daily dose is in a range of about 50 mg to about 250 mg.
18. The method of claim 16 , wherein the route of administration of the compound is selected from the group consisting of oral, topical, intradermal, transdermal, and subcutaneous.
19. The method of claim 12 , wherein the non-melanoma skin cancer is selected from the group consisting of basal cell carcinoma, squamous cell carcinoma, Kaposi's sarcoma, Merkel cell carcinoma, and cutaneous lymphoma.
20. The method of claim 19 , wherein the non-melanoma skin cancer is squamous cell carcinoma.
21. The method of claim 20 , further wherein 12-HETE levels are reduced in the squamous cell carcinoma.
22. The method of claim 12 , further wherein 12-HETE levels are reduced in the non-melanoma skin cancer.